Steven Mark Wenglowsky

This inventor holds 12 USPTO granted patents and 5 published patent applications and 1 EPO patent. Top assignee: Blueprint Medicines Corporation. Active years: 2016-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Steven Mark Wenglowsky. Retrieved from https://idiyas.com/inventor/steven-mark-wenglowsky

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 12 (Patent Applications = 5)

% Patents Active = 91.7

EPO Patents = 1 (Patent Applications = 12)

Average Co-Inventor Count = 5.4

ph-index = 6

Forward Citations = 141(Granted Patents)

Company Filing History:

12 out of 72

Blueprint Medicines Corporation

patents

Years Active: 2016-2026

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12668585 - Substituted pyrimidinyl-pyrazoles as CDK2 inhibitors (2026-06-30),

2. 12545684 - CDK2 inhibitors (2026-02-10),

3. 11970498 - CDK2 inhibitors (2024-04-30),

4. 11932648 - CDK2 inhibitors (2024-03-19),

5. 11059827 - Compounds and compositions useful for treating disorders related to NTRK (2021-07-13),

6. 11046697 - Compounds and compositions useful for treating disorders related to NTRK (2021-06-29),

7. 10774070 - 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors (2020-09-15),

8. 10370379 - Compounds and compositions useful for treating disorders related to NTRK (2019-08-06),

9. 10202365 - 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors (2019-02-12),

10. 10017512 - Compounds and compositions useful for treating disorders related to NTRK (2018-07-10),

11. 9994552 - Compositions useful for treating disorders related to kit (2018-06-12),

12. 9499522 - Compositions useful for treating disorders related to kit (2016-11-22),

Title: Innovator Spotlight: Steven Mark Wenglowsky

Introduction: Steven Mark Wenglowsky is a distinguished inventor based in Cambridge, MA, recognized for his significant contributions to the field of pharmaceuticals. With a portfolio of ten patents, Wenglowsky has dedicated his efforts to research that aims to combat cancer through innovative compounds.

Latest Patents: Among his recent advancements, Wenglowsky has developed CDK2 inhibitors, which are compounds represented by a specific structural formula. These compounds or their pharmaceutically acceptable salts hold promise for treating various types of cancer, reflecting his commitment to creating life-saving therapies.

Career Highlights: Wenglowsky is currently employed at Blueprint Medicines Corporation, where he continues his groundbreaking work in cancer treatment. His extensive experience and innovative approach have established him as a pivotal figure in the pharmaceutical industry, driving forward the development of new treatments.

Collaborations: In his professional journey, Wenglowsky collaborates closely with notable colleagues such as Joseph L Kim and Chandrasekhar V Miduturu. These partnerships enhance the research and development process, fostering an environment of innovation that is crucial in the fight against cancer.

Conclusion: Steven Mark Wenglowsky stands out as an inventor whose work is changing the landscape of cancer treatment. Through his patents and collaborations, he exemplifies the spirit of innovation that drives the pharmaceutical field forward. His commitment to developing effective therapies serves as an inspiration for future inventors and researchers.

Profile summary based on public USPTO records.